Remedy Cell Launches Phase 1b Trial for RC-0315 to Treat IPF Patients Remedy Cell initiates a Phase 1b clinical trial for RC-0315, offering hope to patients with idiopathic pulmonary fibrosis (IPF). This study evaluates safety, tolerability, and potential efficacy.

Remedy Cell Launches Phase 1b Trial for RC-0315 to Treat IPF Patients #None #Haifa #IPF #Remedy_Cell #RC-0315

Remedy Cell and Qureight Join Forces to Enhance Fibrosis Treatments with AI Technology Remedy Cell partners with Qureight to incorporate deep learning into the Phase 1b study of RC-0315, targeting idiopathic pulmonary fibrosis and enhancing treatment outcomes.

Remedy Cell and Qureight Join Forces to Enhance Fibrosis Treatments with AI Technology #Cambridge #United_Kingdom #Remedy_Cell #Qureight #RC-0315